Vistin Pharma ASA (FRA:VP4) Other Current Receivables: €2.52 Mil (As of Mar. 2026)


FRA:VP4 Vistin Pharma ASA FRA:VP4
80 GF Score
Price €1.79
GF Value €2.27
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Other Current Receivables?

Vistin Pharma ASA FRA:VP4 -1.10% 80 Other Current Receivables is €2.52 Mil as of Mar. 2026. GuruFocus rates FRA:VP4 with a GF Score™ of 80/100 and a GF Value™ of €2.27 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Vistin Pharma ASA's Other Current Receivables for the quarter that ended in Mar. 2026 was €2.52 Mil.

Vistin Pharma ASA's quarterly Other Current Receivables increased from Sep. 2025 (€0.86 Mil) to Dec. 2025 (€0.88 Mil) and increased from Dec. 2025 (€0.88 Mil) to Mar. 2026 (€2.52 Mil).

Vistin Pharma ASA's annual Other Current Receivables declined from Dec. 2023 (€1.09 Mil) to Dec. 2024 (€0.66 Mil) but then increased from Dec. 2024 (€0.66 Mil) to Dec. 2025 (€0.88 Mil).

Vistin Pharma ASA Other Current Receivables Related Terms

Vistin Pharma ASA Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Other Current Receivables Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.48 1.09 0.66 0.88

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 1.00 0.86 0.88 2.52
FRA:VP4
80GF Score
Vistin Pharma ASA FRA:VP4
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €2.52 Mil mean?
Vistin Pharma ASA (FRA:VP4) has a Other Current Receivables of €2.52 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Other Current Receivables too high?
Vistin Pharma ASA's current Other Current Receivables is €2.52 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Other Current Receivables compare to ZTS and UTHR?
Vistin Pharma ASA's Other Current Receivables of €2.52 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Other Current Receivables is €2.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (FRA:VP4) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.27, compared to a current price of €1.79 — trading 21.1% below its estimated fair value. The current Other Current Receivables is €2.52 Mil. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Vistin Pharma ASA (FRA:VP4), the current Other Current Receivables is €2.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (FRA:VP4) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of €1.79 is trading 21.1% below its estimated GF Value™ of €2.27. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for FRA:VP4:

  • Other Current Receivables: €2.52 Mil
  • GF Value™: €2.27 vs. price of €1.79 (21.1% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the FRA:VP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score

Get the complete analysis for FRA:VP4

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.79
Price
€2.27
GF Value